StocksMediumUpdated•Originally published 30 September 2026•Updated 30 September 2026•
1 min read
Rafael Holdings Stock Tumbles 25% on Mixed Phase 3 Results for Trappsol Cyclo
Key Facts
1Trappsol Cyclo did not achieve statistical significance on the primary endpoint but showed a statistically significant effect in a prespecified subgroup analysis.
2Rafael Holdings remains on track to submit a New Drug Application (NDA) in the fourth quarter of 2026.
Rafael Holdings stock tumbled 25% after the company announced that its drug Trappsol Cyclo did not achieve statistical significance on the primary endpoint of the Phase 3 TransportNPC study. According to a statement released via GlobeNewswire, the treatment did demonstrate a statistically significant effect in a prespecified subgroup analysis despite missing the broader primary goal.
The company plans to submit a New Drug Application (NDA) in the fourth quarter of 2026 based on the study findings. Shares of RFL were trading at $1.52 on September 30, 2026 following the decline, compared to a previous close of $2.03 on September 29, 2026.